In addition to managing postmenopausal BC through decreasing circulating levels of oestradiol via inhibition of aromatase [12], the steroid sulphatase (STS) pathway, a second major pathway for estrogen biosynthesis, can also be targeted. Here, CYP19A1 is linked to breast cancer.